“I never lose. I either win or learn.”
Daniel Lee, MD is an accomplished physician executive, psychiatrist, psychopharmacologist, clinical scientist, and former U.S. Food and Drug Administration Medical Officer whose career has been defined by a commitment to rigorous science, ethical leadership, and the advancement of innovative treatments for central nervous system conditions. Across approximately two decades of professional experience, Dr. Lee has worked at the intersection of medicine, clinical research, pharmaceutical development, regulatory strategy, public policy, and organizational leadership. His perspective has been shaped by service as a U.S. Army officer, frontline clinical practice, federal regulatory responsibility, senior pharmaceutical leadership, and independent consulting. Throughout these diverse environments, he has remained focused on a central mission: leading with transparency and rigorous ethical standards while championing cutting-edge research, building public trust, and guiding high-performing teams in the development of meaningful new treatments for patients. Daniel has extensive experience working closely with pharmaceutical executives and boards, including representing pharmaceutical companies on investor calls and directly advising boards in his capacity as a consultant. His consulting work places him alongside C suite leadership teams on a daily basis, providing strategic guidance and helping senior decision makers navigate complex business and industry priorities.
Dr. Lee began building the scientific and leadership foundations of his career at DeSales University, earning a Bachelor of Science in Biology and Psychology with a minor in Neuroscience before receiving his Doctor of Medicine from the Uniformed Services University of the Health Sciences. He subsequently completed his psychiatry residency at Walter Reed National Military Medical Center. His medical training was accompanied by a decade of service as a commissioned U.S. Army officer, ultimately reaching the rank of Major. That experience exposed him early in his career to environments in which leadership, accountability, evidence-based decision-making, and the ability to remain effective under pressure were essential. His military service also provided a foundation for his later work across clinical research, healthcare policy, pharmaceutical development, and executive leadership.
During his military medical career, Dr. Lee assumed responsibilities that extended well beyond conventional psychiatric practice. At Fort Polk, Louisiana, he served as the only psychiatrist for much of his assignment while simultaneously taking on leadership responsibilities across multiple behavioral health services. He provided oversight and management for more than 20 government civilian and contract employees, directly supervised 16 employees, and served as a voting member of numerous hospital committees. He also provided consultation to military commanders and cared for a complex patient population that included individuals at elevated psychiatric risk. These experiences strengthened his ability to balance individual patient needs, organizational priorities, resource limitations, and institutional responsibilities while maintaining high standards of clinical care.
Dr. Lee’s interest in evidence-based medicine evolved into significant work in research and healthcare policy. As a research scientist, he conducted critical assessments, systematic reviews, meta-analyses, and bias evaluations of psychiatric and neurological research while contributing technical expertise to Department of Defense behavioral health and traumatic brain injury initiatives. His work included contributions associated with VA/DoD clinical practice guideline development, including PTSD, and consultation on complex questions involving treatment-resistant psychiatric disorders, research methodology, psychometrics, and clinical outcomes. His academic work has subsequently appeared in respected publications including JAMA Neurology, JAMA Psychiatry, Depression and Anxiety, Current Psychiatry Reports, Academic Psychiatry, and the Journal of Clinical Psychiatry. This combination of clinical experience and methodological rigor established a recurring theme in his career: challenging assumptions through evidence and translating complex scientific findings into practical decisions.
A defining chapter of Dr. Lee’s professional development came when he joined the U.S. Food and Drug Administration as a Medical Officer and Clinical Reviewer. Working within the Division of Psychiatry Products, he directly oversaw hundreds of commercial and academic CNS Investigational New Drug applications involving Phase I through Phase IV clinical trials and served as the primary clinical reviewer for multiple New Drug Applications. He participated in the planning and execution of FDA advisory committees, formally represented the agency as a presenter, contributed to official policy guidance for industry, met with pharmaceutical sponsors to discuss drug-development programs, and regularly prepared official FDA communications. His work also included developing and refining regulatory approaches involving emerging areas such as psychedelic drugs and drug products incorporating embedded devices. This experience gave Dr. Lee an uncommon understanding of how regulators evaluate scientific evidence, patient safety, benefit-risk considerations, development strategy, and the quality of the arguments supporting a potential new therapy.
Dr. Lee carried this regulatory perspective into the pharmaceutical industry, joining Otsuka Pharmaceutical and progressing from Associate Director to Director of Global Clinical Development. During his tenure, he became a clinical development and asset leader for major CNS programs involving brexpiprazole and aripiprazole. His responsibilities encompassed clinical strategy, trial design and execution, medical monitoring, regulatory compliance, development planning, and commercialization strategy. He also participated in due diligence and business-development activities and worked across co-development alliances with external organizations. His work placed him at the center of multidisciplinary decisions requiring clinical, scientific, regulatory, operational, and commercial considerations to be brought together around a coherent development strategy.
His leadership in pharmaceutical development continued as Senior Medical Director at Xenon Pharmaceuticals, where he served as a clinical development leader for psychiatric studies involving azetukalner. In this capacity, Dr. Lee helped shape clinical design, trial execution, medical monitoring, regulatory compliance, and broader development and commercialization strategies for psychiatric indications. Across his pharmaceutical career, his clinical-development experience has encompassed programs involving major depressive disorder, bipolar depression, posttraumatic stress disorder, schizophrenia, generalized anxiety disorder, agitation associated with Alzheimer’s dementia, autism spectrum disorder, and other CNS conditions. His experience across development stages allows him to examine an asset not merely as a scientific hypothesis, but as a potential therapy that must successfully navigate clinical evidence generation, regulatory scrutiny, patient safety requirements, operational execution, and ultimately real-world medical need.
Scientific publication and intellectual curiosity have remained important elements of Dr. Lee’s professional identity. Among his research contributions is his co-authorship of a randomized clinical trial examining brexpiprazole for agitation associated with Alzheimer’s dementia, published in JAMA Neurology. His broader publication record encompasses PTSD treatment, psychiatric screening, research methodology, psychopharmacology, military medicine, and CNS clinical development. He has also contributed to book chapters and clinical practice guidance and has served as a reviewer for academic medical publications. This sustained involvement with the scientific literature reflects his conviction that strong strategic decisions begin with a disciplined understanding of evidence, including both what the evidence demonstrates and where its limitations remain.
Today, Dr. Lee extends this multidisciplinary experience through Psychopharmacology & Regulatory Consulting, Inc., providing independent consulting and expert-witness services. His consulting work has included advising pharmaceutical companies, biotechnology organizations, and financial institutions on clinical-trial design, investment considerations, pharmaceutical and technology development, medical and psychiatric safety monitoring, and FDA regulatory matters. His expertise is particularly relevant to organizations confronting difficult questions surrounding CNS development programs, regulatory pathways, clinical evidence, safety, and the potential value of pharmaceutical assets. His experience on multiple sides of the development ecosystem enables him to understand the priorities of regulators, clinicians, researchers, sponsors, investors, and ultimately the patients whom new therapies are intended to serve.
For board and advisory service, Dr. Lee brings a perspective built from experiences that rarely coexist within a single executive career. He has treated patients directly, led clinical organizations, managed multidisciplinary teams, evaluated scientific evidence, contributed to military healthcare policy, reviewed drug-development programs from inside the FDA, led pharmaceutical assets from within industry, participated in due diligence and business-development discussions, and advised organizations independently. This breadth enables him to identify clinical and regulatory risks early, ask probing questions about development assumptions, evaluate whether evidence supports strategic conclusions, and help leadership teams connect scientific decisions with broader organizational objectives. He is particularly interested in pharmaceutical and psychiatric opportunities while remaining open to organizations of different sizes and industries where his expertise and leadership perspective can create meaningful value.
Underlying Dr. Lee’s professional achievements is a personal philosophy centered on resilience, continuous learning, transparency, and accountability. His motto, “I never lose. I either win or learn,” reflects an approach in which setbacks are treated as opportunities to extract insight, refine strategy, and improve future performance. Outside his professional life, he has pursued interests that require a different form of discipline and continual improvement, including competitive ballroom and Latin dance, ballet, bodybuilding, fitness, acting, modeling, nutrition, and tabletop roleplaying games. These pursuits reflect the curiosity and willingness to challenge himself that have characterized his professional development as well.
As Dr. Lee looks toward board and advisory opportunities, he offers organizations more than specialized knowledge of psychiatry or pharmaceutical development. He brings an integrated understanding of how scientific innovation becomes a credible clinical-development strategy, how that strategy is evaluated by regulators, how multidisciplinary teams must execute against it, and how leadership can maintain public and organizational trust while pursuing ambitious objectives. His career demonstrates an ability to operate across scientific, medical, regulatory, and strategic environments while remaining grounded in evidence and ethical responsibility. For organizations developing innovative therapies or navigating complex healthcare and life-sciences challenges, Dr. Lee brings the experience to contribute thoughtful oversight, challenge assumptions constructively, and help leadership teams transform promising ideas and assets into disciplined strategies capable of producing meaningful outcomes.
Character:
Dr. Lee approaches leadership with an emphasis on transparency, ethical standards, resilience, and personal accountability. His military service, clinical responsibilities, regulatory work, and pharmaceutical leadership demonstrate a career grounded in responsibility to patients, colleagues, institutions, and the integrity of scientific decision-making.
Knowledge:
Combining expertise in psychiatry, psychopharmacology, CNS clinical research, pharmaceutical development, FDA regulation, clinical-trial methodology, and drug safety with direct experience across Phase I–IV programs. His perspective is strengthened by having participated in drug development as a clinician, researcher, regulator, pharmaceutical executive, and independent consultant.
Strategic:
Dr. Lee understands that successful pharmaceutical development requires scientific evidence, regulatory planning, clinical execution, risk assessment, and commercial considerations to work together rather than independently. His experience leading development-stage assets, participating in due diligence, navigating regulatory interactions, and contributing to lifecycle strategies allows him to examine both immediate development decisions and their longer-term implications.
Communication:
He has translated complex medical and scientific concepts for regulators, pharmaceutical sponsors, clinicians, researchers, executives, multidisciplinary teams, and other stakeholders throughout his career. His experience as an FDA presenter, educator, consultant, published researcher, and public speaker supports his ability to communicate technical information clearly while encouraging informed, evidence-driven discussion.
